Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082762 | 0.71 | NPC1 (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4843148 | 0.68 | — | — | |
| SCHEMBL4452760 | 0.68 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL3674913 | 0.68 | KDM4E (0.33) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL3759300 | 0.68 | MDM2 (0.31) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4794205 | 0.68 | CYP1A2 (0.30) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2182857 | 0.68 | KDM4E (0.48) | CYP1A2CYP2C9CYP2C19NPC1RAB9A | |
| SCHEMBL1706101 | 0.68 | — | — | |
| SCHEMBL8183045 | 0.65 | ALDH1A1 (0.43) | NPC1RAB9AKDM4E | |
| SCHEMBL467328 | 0.65 | MDM2 (0.35) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781512-B1 | OXADIAZOLE COMPOUND AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | UNIV SHANGHAI JIAOTONG (CN) | 2017-06-28 | — | — | EP | claimed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-8981104-B2 | 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-17 | — | — | US | disclosed |
| US-8957084-B2 | 7,8-cyclicmorphinan analogs | PURDUE PHARMA L.P. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140187571-A1 | 7,8-Cyclicmorphinan Analogs | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8673903-B2 | Substituted 8-alkoxy-2-aminotetralin derivatives, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20130203751-A1 | SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-08 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-8354446-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED | 2010-10-07 | — | — | US | disclosed |
| US-7645753-B2 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | US | disclosed |
| US-20040116454-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-17 | — | — | US | disclosed |
| US-6713632-B1 | Process for the preparation of imidazole derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| EP-1193258-A1 | PROCESS FOR THE PREPARATION OF IMIDAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-04-03 | — | — | EP | disclosed |
| US-6048885-A | FUNGICIDES | SHIONOGI & CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | CYP1A2 669/4885CYP2D6 369/4885CYP19A1 2149/4885 |
| US-20140031391-A1 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use | TNNT2, TNNI3, FABP3 | CYP1A2 320/4885CYP2D6 523/4885CYP19A1 2955/4885 |
| US-20100256129-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | AR, NR5A1, SHBG | CYP1A2 526/4885CYP2D6 960/4885CYP19A1 12/4885 |
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE3B | CYP1A2 174/4885CYP2D6 327/4885CYP19A1 140/4885 |
| US-20140187571-A1 | 7,8-Cyclicmorphinan Analogs | OPRL1, OPRM1, AVPR1A | CYP1A2 355/4885CYP2D6 310/4885CYP19A1 520/4885 |
| US-20130203751-A1 | SUBSTITUTED 8-ALKOXY-2-AMINOTETRALIN DERIVATIVES, AND USE THEREOF | AADAT, TNNT2, TNNI3 | CYP1A2 238/4885CYP2D6 166/4885CYP19A1 2644/4885 |
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | SSTR5, SSTR1, SSTR2 | CYP1A2 451/4885CYP2D6 552/4885CYP19A1 610/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | CYP1A2 1927/4885CYP2D6 3460/4885CYP19A1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.